Adamas Pharmaceuticals Inc.

4.83+0.0500+1.05%Vol 31.07K1Y Perf 1.26%
Sep 23rd, 2021 13:04 DELAYED
BID4.83 ASK4.85
Open4.83 Previous Close4.78
Pre-Market- After-Market-
 - -%  - -
Target Price
7.92 
Analyst Rating
Moderate Buy 1.71
Potential %
63.98 
Finscreener Ranking
★★★     49.46
Insiders Trans % 3/6/12 mo.
-/-100/-78 
Value Ranking
★★     47.25
Insiders Value % 3/6/12 mo.
-/-100/-63 
Growth Ranking
★★★     53.72
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-61 
Income Ranking
 —    -
Price Range Ratio 52W %
30.21 
Earnings Rating
Buy
Market Cap220.23M 
Earnings Date
4th Nov 2021
Alpha-0.03 Standard Deviation0.25
Beta2.68 

Today's Price Range

4.744.89

52W Range

2.969.15

5 Year PE Ratio Range

-4.90-1.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
0.63%
1 Month
3.24%
3 Months
-10.49%
6 Months
-9.13%
1 Year
1.26%
3 Years
-75.07%
5 Years
-72.45%
10 Years
-

TickerPriceChg.Chg.%
ADMS4.830.05001.05
AAPL146.800.95000.65
GOOG2 840.4321.66000.77
MSFT300.071.49000.50
XOM57.121.91003.46
WFC48.101.02002.17
JNJ165.631.70001.04
FB346.182.97000.87
GE104.035.49005.57
JPM161.465.55003.56
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.30
0.96
22.86
-3.20
Leverage Ratio -7.00
ProfitabilityValueIndustryS&P 500US Markets
97.60
-51.00
-50.20
-5 429.90
-66.46
RevenueValueIndustryS&P 500US Markets
82.47M
1.81
60.16
188.50
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.27-0.270.00
Q01 2021-0.48-0.3625.00
Q04 2020-0.53-0.64-20.75
Q03 2020-0.50-0.4216.00
Q02 2020-0.61-0.3739.34
Q01 2020-0.75-0.5921.33
Q04 2019-0.89-0.836.74
Q03 2019-0.90-0.99-10.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.220.00-
12/2021 QR-0.1715.00Positive
12/2021 FY-1.013.81Positive
12/2022 FY-0.45-25.00Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.22
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume31.07K
Shares Outstanding45.60M
Shares Float40.65M
Trades Count282
Dollar Volume24.37M
Avg. Volume443.23K
Avg. Weekly Volume176.80K
Avg. Monthly Volume153.38K
Avg. Quarterly Volume231.05K

Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) stock closed at 4.78 per share at the end of the most recent trading day (a -2.05% change compared to the prior day closing price) with a volume of 106.70K shares and market capitalization of 220.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 138 people. Adamas Pharmaceuticals Inc. CEO is Neil F. McFarlane.

The one-year performance of Adamas Pharmaceuticals Inc. stock is 1.26%, while year-to-date (YTD) performance is 10.39%. ADMS stock has a five-year performance of -72.45%. Its 52-week range is between 2.96 and 9.15, which gives ADMS stock a 52-week price range ratio of 30.21%

Adamas Pharmaceuticals Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 35.33, a price-to-sale (PS) ratio of 2.65, a price to cashflow ratio of 23.20, a PEG ratio of 2.32, a ROA of -37.87%, a ROC of -43.27% and a ROE of 369.95%. The company’s profit margin is -66.46%, its EBITDA margin is -50.20%, and its revenue ttm is $82.47 Million , which makes it $1.81 revenue per share.

Of the last four earnings reports from Adamas Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Adamas Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Adamas Pharmaceuticals Inc. is Moderate Buy (1.71), with a target price of $7.92, which is +63.98% compared to the current price. The earnings rating for Adamas Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamas Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamas Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.80, ATR14 : 0.25, CCI20 : 111.81, Chaikin Money Flow : 0.06, MACD : 0.03, Money Flow Index : 63.60, ROC : 0.63, RSI : 52.38, STOCH (14,3) : 54.24, STOCH RSI : 0.37, UO : 61.59, Williams %R : -45.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamas Pharmaceuticals Inc. in the last 12-months were: Christopher B. Prentiss (Sold 10 923 shares of value $55 753 ), David L. Mahoney (Option Excercise at a value of $31 920), John A. Macphee (Option Excercise at a value of $127 680), Martha J. Demski (Sold 2 000 shares of value $10 340 ), Spyridon Papapetropoulos (Buy at a value of $30 234), Vijay Shreedhar (Sold 11 765 shares of value $66 608 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.71
Moderate Buy
1.71
Moderate Buy
1.71

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Neil F. McFarlane

Telephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, US

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

60%40%

Bearish Bullish

56%44%

TipRanks News for ADMS

Tue, 10 Aug 2021 13:54 GMT Adamas Pharmaceuticals (ADMS) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits